Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


Testing blood samples for levels of neurofilament light chains (NfLs) can identify patients with multiple sclerosis, as well as indicate degree of disease activity, new research suggests.

...

A new Tel Aviv University study published in the Journal of the American Chemical Society (JACS) pinpoints a structural instability in the myelin membranes, the "insulating tape" surrounding...

A newly discovered potential biomarker of MS may help to distinguish between people who will go on to have less severe disease and those in whom the disease will progress, researchers at Linköping...

Results from the extension period of a Phase II trial, assessing Ozanimod as a potential treatment for relapsing-remitting multiple sclerosis, showed that the drug can effectively and safely...

Results from the ORATORIO trial, exploring Ocrevus (ocrelizumab), for the treatment of primary progressive forms of MS, have shown the drug stopped disease progression for more than two years in...

Scientists are investigating a way to use temporary tattoos that deliver nanoparticles to treat autoimmune diseases like multiple sclerosis.

“Placed just under the skin, the carbon-based...

The U.S. Department of Health and Human Services (HHS) recently announced policy changes designed to make information about clinical trials of investigational drugs, biologics and products more...

A drug currently being developed for people living with multiple sclerosis has shown promising results to stop the progression of the disease in mice. Known as Laquinimod, it is being tested in...

Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) a Novartis report found that siponimod (BAF312) reduced the risk of disability progression in a Phase...

Lemtrada (alemtuzumab) as a first treatment option for relapsing multiple sclerosis reduced relapse rates and disability progression throughout a study period of six years — although most patients...

Pages

Live Chat Software by Click4Assistance UK